Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05911295 |
| Title | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Seagen, a wholly owned subsidiary of Pfizer |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | SWE | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | CZE | CAN | BRA | BEL | AUS | ARG |